Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir in CMV-infected IBD
NCT00237653Phase 3Terminated
- Sponsor
- CHU Grenoble Alpes
- Start
- Feb 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valganciclovir in inflammatory bowel disease (IBD), cytomegalovirus infection (CMV), sponsored by CHU Grenoble Alpes. Started Feb 2004; status: terminated.
02
Drugs
valganciclovir
03
Conditions
inflammatory bowel disease (IBD)cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00237653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237653.